The study to examine the appropriate skin dose in intensity modulated radiotherapy with cetuximab

The study to examine the appropriate skin dose in intensity modulated radiotherapy with cetuximab - The study to examine the appropriate skin dose in intensity modulated radiotherapy with cetuximab

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019717

Enrollment

Registered

2015-11-10

Start date

2015-11-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and neck cancer

Interventions

Intensity modulated radiotherapy (more than 60 Gy) with concurrent use of cetuximab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Locally advanced head and neck carcinoma Concurrent use of cetuximab Intensity modulated radiotherapy The number of lymph node region irradiated is equal to or more than 2 Age over 20 PS 0-2 Written informed consent

Exclusion criteria

Exclusion criteria: Severe coexisting disease Synchronous malignancies Pregnancy, possible pregnancy

Design outcomes

Primary

Measure	Time frame
Phase I: Acute skin toxicity Phase II: Response rate(at the 8 weeks after radiotherapy)	—

Secondary

Measure	Time frame
Locoregional progression free survival Progression free survival Overall survival Adverse events	—

Countries

Japan

Contacts

Public ContactKoji Inaba

National Cancer Center Hospital, Japan Department of Radiation Oncology

koinaba@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026